News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biota Holdings Limited (BTA.AX) Release: Inavir(R) Approved for Sale in Japan



9/13/2010 10:15:22 AM

MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® (pronounced in-a-veer) in Japan. Inavir® is Daiichi Sankyo’s brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

Read at BioSpace.com


comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES